NO20085397L - Pyridinon- og pyridazinonderivater som inhibitorer av poly(ADP-ribose)polymerase (PARP) - Google Patents
Pyridinon- og pyridazinonderivater som inhibitorer av poly(ADP-ribose)polymerase (PARP)Info
- Publication number
- NO20085397L NO20085397L NO20085397A NO20085397A NO20085397L NO 20085397 L NO20085397 L NO 20085397L NO 20085397 A NO20085397 A NO 20085397A NO 20085397 A NO20085397 A NO 20085397A NO 20085397 L NO20085397 L NO 20085397L
- Authority
- NO
- Norway
- Prior art keywords
- parp
- adp
- ribose
- polymerase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
Abstract
Den foreliggende oppfinnelse vedrører forbindelser med formel I: og farmasøytisk akseptable salter eller tautomerer derav som er inhibitorer av poly(ADP-ribose)polymerase (PARP) og således er anvendbare til behandlingen av kreft, inflammatoriske sykdommer, reperfusjonsskader, iskemiske tilstander, slag, nyresvikt, hjerte- og karsykdommer, andre karsykdommer enn hjerte- og karsykdommer, diabetes meilitus, neurodegenerative sykdommer, retrovirusinfeksjoner, retinal skade, hudaldring og UV-indusert hudskade, og som kjemo- eller strålingssensitivi-serende midler for kreftbehandling.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0610680.1A GB0610680D0 (en) | 2006-05-31 | 2006-05-31 | Therapeutic compounds |
PCT/GB2007/050295 WO2007138351A2 (en) | 2006-05-31 | 2007-05-25 | Pyridinone and pyridazinone derivatives as inhibitors of poly(adp-ribose)polymerase (parp) |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20085397L true NO20085397L (no) | 2009-02-25 |
NO343950B1 NO343950B1 (no) | 2019-07-22 |
Family
ID=36694627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20085397A NO343950B1 (no) | 2006-05-31 | 2008-12-29 | Pyridinon- og pyridazinonderivater som inhibitorer av poly(ADP-ribose)polymerase (PARP), samt farmasøytisk preparat, og farmasøytisk kombinasjon derav for anvendelse i terapi |
Country Status (16)
Country | Link |
---|---|
US (1) | US8188084B2 (no) |
EP (1) | EP2029551B1 (no) |
JP (1) | JP5351755B2 (no) |
KR (1) | KR101529891B1 (no) |
CN (2) | CN103420988A (no) |
AU (1) | AU2007266836B2 (no) |
BR (1) | BRPI0711741B8 (no) |
CA (1) | CA2653529C (no) |
ES (1) | ES2702781T3 (no) |
GB (1) | GB0610680D0 (no) |
IL (1) | IL195113A (no) |
MX (1) | MX2008015014A (no) |
NO (1) | NO343950B1 (no) |
NZ (1) | NZ572815A (no) |
WO (1) | WO2007138351A2 (no) |
ZA (1) | ZA200809238B (no) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0622195D0 (en) * | 2006-11-08 | 2006-12-20 | Angeletti P Ist Richerche Bio | Therapeutic agents |
AU2008322676B9 (en) * | 2007-11-15 | 2014-03-27 | Msd Italia S.R.L. | Pyridazinone derivatives as PARP inhibitors |
DE102008019907A1 (de) * | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
JP5654001B2 (ja) * | 2009-04-29 | 2015-01-14 | グラクソ グループ リミテッドGlaxo Group Limited | P2X7調節因子としての5,6,7,8−テトラヒドロ[1,2,4]トリアゾロ[4,3−a]ピラジン誘導体 |
GB0907515D0 (en) * | 2009-04-30 | 2009-06-10 | Glaxo Group Ltd | Compounds |
ES2627688T3 (es) | 2010-04-02 | 2017-07-31 | Ogeda Sa | Novedosos compuestos antagonistas selectivos del receptor de NK-3, composición farmacéutica y métodos para uso en trastornos mediados por los receptores de NK-3 |
US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
AU2011251622A1 (en) | 2010-05-10 | 2012-12-20 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
CN102372716A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
EP2714703B1 (en) | 2011-05-31 | 2021-03-10 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
CN103906750B9 (zh) | 2011-10-03 | 2016-10-12 | 欧洲筛选有限公司 | 作为选择性NK-3受体拮抗剂的新型手性N-酰基-5,6,7,(8-取代的)-四氢-[1,2,4]三唑并[4,3-a]吡嗪、药物组合物、用于NK-3受体介导的疾病中的方法及其手性合成 |
CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
CN103833756B (zh) * | 2012-11-26 | 2016-12-21 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和用途 |
ES2469990B1 (es) * | 2012-12-19 | 2015-01-26 | Universidade De Vigo | Compuestos de estructura híbrida piridazinona ditiocarbamato con actividad antineoplásica |
BR112015012425A2 (pt) * | 2012-12-31 | 2017-07-11 | Cadila Healthcare Ltd | composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto |
EP3757093A1 (en) * | 2013-03-13 | 2020-12-30 | Chugai Seiyaku Kabushiki Kaisha | Dihydropyridazine-3,5-dione derivative |
PE20160122A1 (es) | 2013-03-13 | 2016-02-12 | Forma Therapeutics Inc | Compuestos nobles y composiciones para la inhibicion de fasn |
US10183948B2 (en) | 2013-03-29 | 2019-01-22 | Ogeda Sa | N-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists |
WO2014154896A1 (en) | 2013-03-29 | 2014-10-02 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-5,6,7,8-TETRAHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
SG11201508005XA (en) | 2013-03-29 | 2015-10-29 | Euroscreen Sa | NOVEL N-ACYL-(3-SUBSTITUTED)-(8-SUBSTITUTED)-5,6-DIHYDRO- [1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS |
US9840508B2 (en) | 2013-03-29 | 2017-12-12 | Oged Sa | N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a] pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders |
KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
ES2544869B2 (es) * | 2014-03-04 | 2016-01-18 | Universidade De Vigo | Derivados de piridazin-3(2H)-ona inhibidores selectivos de la isoforma B de la monoaminooxidasa |
WO2016054237A2 (en) * | 2014-10-03 | 2016-04-07 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Poly (adp-ribose) polymerase 1 inhibitors structurally unrelated to nad |
US10472664B2 (en) | 2014-10-03 | 2019-11-12 | Institute For Cancer Research | Screening assay for identification of poly(ADP-ribose) polymerase 1 inhibitors |
US11261466B2 (en) | 2015-03-02 | 2022-03-01 | Sinai Health System | Homologous recombination factors |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
CN106749261A (zh) | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
RS60209B1 (sr) | 2017-03-20 | 2020-06-30 | Forma Therapeutics Inc | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) |
CN109232575B (zh) * | 2017-07-10 | 2022-01-25 | 中国科学院上海药物研究所 | 吡咯[1,2-b]哒嗪类化合物或其可药用盐及它们的用途 |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
MA52486B1 (fr) | 2018-04-30 | 2023-04-28 | Ribon Therapeutics Inc | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
CN113382633A (zh) | 2018-10-29 | 2021-09-10 | 福马治疗股份有限公司 | (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式 |
AR120338A1 (es) | 2019-10-30 | 2022-02-09 | Ribon Therapeutics Inc | Piridazinonas como inhibidores de parp7 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
MX2022013304A (es) | 2020-04-21 | 2022-12-15 | Idience Co Ltd | Formas cristalinas de compuesto de ftalazinona. |
CN117083274A (zh) * | 2021-04-23 | 2023-11-17 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药(上海)有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CN115745971A (zh) * | 2021-12-20 | 2023-03-07 | 重庆华森制药股份有限公司 | Parp7抑制剂及其应用 |
AU2022451580A1 (en) * | 2022-04-01 | 2023-12-14 | Novostar Pharmaceuticals, Ltd. | Parp7 inhibitor and use thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
CN1136197C (zh) * | 1996-05-30 | 2004-01-28 | 霍夫曼-拉罗奇有限公司 | 新的哒嗪酮衍生物 |
EP1330442B1 (en) | 2000-10-30 | 2011-01-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
ATE355278T1 (de) | 2001-05-08 | 2006-03-15 | Kudos Pharm Ltd | Isochinolinon derivate als parp inhibitoren |
EP1411941A2 (en) * | 2001-08-02 | 2004-04-28 | Neurocrine Biosciences, Inc. | Pyridinone and pyridazinone derivatives as gonadotropin-releasing hormone receptor antagonists |
WO2003017369A1 (en) | 2001-08-14 | 2003-02-27 | Transchip, Inc. | A pixel sensor with charge evacuation element and systems and methods for using such |
ATE491703T1 (de) | 2002-04-30 | 2011-01-15 | Kudos Pharm Ltd | Phthalazinonderivate |
PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
WO2004085406A1 (en) * | 2003-03-24 | 2004-10-07 | F. Hoffmann-La Roche Ag | Benzyl-pyridazinons as reverse transcriptase inhibitors |
EP1730120A1 (en) * | 2004-03-23 | 2006-12-13 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
JP2007532592A (ja) | 2004-04-15 | 2007-11-15 | エフ.ホフマン−ラ ロシュ アーゲー | ピリダジノン化合物の製造方法 |
JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | 4−ヘテロアリールメチル置換フタラジノン誘導体 |
DE602006016821D1 (de) * | 2005-07-21 | 2010-10-21 | Hoffmann La Roche | Pyridazinonderivate als schilddrüsenhormon-rezeptoragonisten |
JP2009510013A (ja) * | 2005-09-30 | 2009-03-12 | エフ.ホフマン−ラ ロシュ アーゲー | Nnrt阻害剤 |
EP2007733B1 (en) * | 2006-04-03 | 2016-05-25 | MSD Italia S.r.l. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
JP5271897B2 (ja) * | 2006-05-31 | 2013-08-21 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | ポリ(ADP−リボース)ポリメラーゼ(PARP)の阻害剤としての、ピロロ[1,2−a]ピラジン−1(2H)−オン及びピロロ[1,2−d][1,2,4]トリアジン−1(2H)−オン誘導体 |
US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
CN103690542B (zh) | 2006-12-28 | 2015-11-18 | Abbvie公司 | 聚(adp-核糖)聚合酶抑制剂 |
US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
TW200900396A (en) | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
WO2011055270A1 (en) * | 2009-11-04 | 2011-05-12 | Wyeth Llc | Indole based receptor crth2 antagonists |
-
2006
- 2006-05-31 GB GBGB0610680.1A patent/GB0610680D0/en not_active Ceased
-
2007
- 2007-05-25 ES ES07733716T patent/ES2702781T3/es active Active
- 2007-05-25 AU AU2007266836A patent/AU2007266836B2/en active Active
- 2007-05-25 NZ NZ572815A patent/NZ572815A/en unknown
- 2007-05-25 WO PCT/GB2007/050295 patent/WO2007138351A2/en active Application Filing
- 2007-05-25 KR KR1020087029132A patent/KR101529891B1/ko active IP Right Grant
- 2007-05-25 US US12/227,513 patent/US8188084B2/en active Active
- 2007-05-25 MX MX2008015014A patent/MX2008015014A/es active IP Right Grant
- 2007-05-25 JP JP2009512681A patent/JP5351755B2/ja active Active
- 2007-05-25 CN CN2013103167261A patent/CN103420988A/zh active Pending
- 2007-05-25 CN CNA2007800201367A patent/CN101501006A/zh active Pending
- 2007-05-25 EP EP07733716.0A patent/EP2029551B1/en active Active
- 2007-05-25 BR BRPI0711741A patent/BRPI0711741B8/pt active IP Right Grant
- 2007-05-25 CA CA2653529A patent/CA2653529C/en active Active
-
2008
- 2008-10-27 ZA ZA200809238A patent/ZA200809238B/xx unknown
- 2008-11-04 IL IL195113A patent/IL195113A/en active IP Right Grant
- 2008-12-29 NO NO20085397A patent/NO343950B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
WO2007138351A2 (en) | 2007-12-06 |
CN101501006A (zh) | 2009-08-05 |
BRPI0711741B8 (pt) | 2021-05-25 |
NO343950B1 (no) | 2019-07-22 |
ZA200809238B (en) | 2009-12-30 |
US8188084B2 (en) | 2012-05-29 |
CA2653529C (en) | 2016-02-09 |
BRPI0711741A2 (pt) | 2011-12-06 |
EP2029551B1 (en) | 2018-10-31 |
BRPI0711741B1 (pt) | 2020-12-29 |
KR20090015092A (ko) | 2009-02-11 |
AU2007266836A1 (en) | 2007-12-06 |
IL195113A0 (en) | 2009-09-22 |
US20090176765A1 (en) | 2009-07-09 |
JP5351755B2 (ja) | 2013-11-27 |
CA2653529A1 (en) | 2007-12-06 |
CN103420988A (zh) | 2013-12-04 |
RU2008152824A (ru) | 2010-07-10 |
IL195113A (en) | 2014-05-28 |
ES2702781T3 (es) | 2019-03-05 |
NZ572815A (en) | 2011-11-25 |
KR101529891B1 (ko) | 2015-06-18 |
EP2029551A2 (en) | 2009-03-04 |
WO2007138351A3 (en) | 2008-08-07 |
JP2009538896A (ja) | 2009-11-12 |
GB0610680D0 (en) | 2006-07-12 |
AU2007266836B2 (en) | 2013-09-26 |
MX2008015014A (es) | 2009-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20085397L (no) | Pyridinon- og pyridazinonderivater som inhibitorer av poly(ADP-ribose)polymerase (PARP) | |
EA200970674A1 (ru) | Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp) | |
MX2010005070A (es) | Derivados de piridazinona como inhibidores de parp. | |
DK2109608T3 (da) | Amid-substituerede indazoler som poly(ADP-ribose)polymerase- (PARP) hæmmere | |
NO20083427L (no) | Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse | |
NO20076450L (no) | Heterosykliske forbindelser som nikotinsyrereseptoragonister for behandling av dyslipidemi | |
WO2008094992A3 (en) | 2-aminopyridine derivatives useful as kinase inhibitors | |
PE20091687A1 (es) | Derivados de piridina o pirazina como inhibidores de cinasa-pi-3 | |
NO20091596L (no) | Benzoylamino-heterocykliske forbindelser som Glucokinase-(GLK)-activatorer | |
WO2007087204A3 (en) | Heterocycles as nicotinic acid receptor agonists for the treatment of dyyslipidemia | |
NO20072608L (no) | Biaryloksymetylarenkarboksylsyrer | |
NO20072963L (no) | 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere | |
WO2008017883A3 (en) | 4-oxo-4,5-dihydropyrrolo[1,2-a] quinoxaline derivatives as inhibitors of poly(adp-ribose)polymerase(parp) | |
WO2006058628A3 (en) | Substituted benzoquinolizines as dpp-iv inhibitors for the treatment of diabetes | |
WO2007076228A8 (en) | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders | |
NO20063865L (no) | Heterocyklisk substituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og deres anvendelse som medikamenter | |
MX2007000576A (es) | Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. | |
NO20080354L (no) | Benzofuranylderivater som 5-HT6-reseptorinhibitorer | |
DE602006003225D1 (de) | Chlorsubstituierte guanidine | |
TH128999A (th) | อนุพันธ์ของ (เฮเทอโรไซเคิล/เททระไฮโดรพิริดีน)-(พิเพแรซินิล)-1-แอลคาโนน และอนุพันธ์ของ (เฮเทอโรไซเคิล/ไดไฮโดรพิร์โรลิดีน)-(พิเพแรซินิล)-1-แอลคาโนน ชนิดใหม่ และการใช้สารนั้นเป็นสารยับยั้ง p75 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MSD ITALIA SRL, IT |